193 related articles for article (PubMed ID: 28548702)
21. A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups.
Ritzmann TA; Rogers HA; Paine SML; Storer LCD; Jacques TS; Chapman RJ; Ellison D; Donson AM; Foreman NK; Grundy RG
Pediatr Blood Cancer; 2020 Sep; 67(9):e28426. PubMed ID: 32614133
[TBL] [Abstract][Full Text] [Related]
22. Molecular subtyping of ependymoma and prognostic impact of Ki-67.
Lim KY; Lee K; Shim Y; Park JW; Kim H; Kang J; Won JK; Kim SK; Phi JH; Park CK; Chung CK; Yun H; Park SH
Brain Tumor Pathol; 2022 Jan; 39(1):1-13. PubMed ID: 34812989
[TBL] [Abstract][Full Text] [Related]
23. Imaging features to distinguish posterior fossa ependymoma subgroups.
Leclerc T; Levy R; Tauziède-Espariat A; Roux CJ; Beccaria K; Blauwblomme T; Puget S; Grill J; Dufour C; Guerrini-Rousseau L; Abbou S; Bolle S; Roux A; Pallud J; Provost C; Oppenheim C; Varlet P; Boddaert N; Dangouloff-Ros V
Eur Radiol; 2024 Mar; 34(3):1534-1544. PubMed ID: 37658900
[TBL] [Abstract][Full Text] [Related]
24. MYCN amplification drives an aggressive form of spinal ependymoma.
Ghasemi DR; Sill M; Okonechnikov K; Korshunov A; Yip S; Schutz PW; Scheie D; Kruse A; Harter PN; Kastelan M; Wagner M; Hartmann C; Benzel J; Maass KK; Khasraw M; Sträter R; Thomas C; Paulus W; Kratz CP; Witt H; Kawauchi D; Herold-Mende C; Sahm F; Brandner S; Kool M; Jones DTW; von Deimling A; Pfister SM; Reuss DE; Pajtler KW
Acta Neuropathol; 2019 Dec; 138(6):1075-1089. PubMed ID: 31414211
[TBL] [Abstract][Full Text] [Related]
25. Molecular profiling of pediatric and adolescent ependymomas: identification of genetic variants using a next-generation sequencing panel.
Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Benevides Silva FA; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
J Neurooncol; 2021 Oct; 155(1):13-23. PubMed ID: 34570300
[TBL] [Abstract][Full Text] [Related]
26. Adult intracranial ependymoma-relevance of DNA methylation profiling for diagnosis, prognosis, and treatment.
Träger M; Schweizer L; Pérez E; Schmid S; Hain EG; Dittmayer C; Onken J; Fukuoka K; Ichimura K; Schüller U; Dührsen L; Müther M; Paulus W; Thomas C; Gutt-Will M; Schucht P; Maragkou T; Schittenhelm J; Eckert F; Niyazi M; Fleischmann DF; Dorostkar MM; Feyer P; May SA; Moskopp D; Badakhshi H; Radke C; Walter J; Ehret F; Capper D; Kaul D
Neuro Oncol; 2023 Jul; 25(7):1286-1298. PubMed ID: 36734226
[TBL] [Abstract][Full Text] [Related]
27. EZHIP: a new piece of the puzzle towards understanding pediatric posterior fossa ependymoma.
Jenseit A; Camgöz A; Pfister SM; Kool M
Acta Neuropathol; 2022 Jan; 143(1):1-13. PubMed ID: 34762160
[TBL] [Abstract][Full Text] [Related]
28. Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system.
Raghunathan A; Wani K; Armstrong TS; Vera-Bolanos E; Fouladi M; Gilbertson R; Gajjar A; Goldman S; Lehman NL; Metellus P; Mikkelsen T; Necesito-Reyes MJ; Omuro A; Packer RJ; Partap S; Pollack IF; Prados MD; Robins HI; Soffietti R; Wu J; Miller CR; Gilbert MR; Aldape KD;
Brain Pathol; 2013 Sep; 23(5):584-94. PubMed ID: 23452038
[TBL] [Abstract][Full Text] [Related]
29. EZH2 expression is a prognostic factor in childhood intracranial ependymoma: a Canadian Pediatric Brain Tumor Consortium study.
Li AM; Dunham C; Tabori U; Carret AS; McNeely PD; Johnston D; Lafay-Cousin L; Wilson B; Eisenstat DD; Jabado N; Zelcer S; Silva M; Scheinemann K; Fryer C; Hendson G; Fotovati A; Hawkins C; Yip S; Dunn SE; Hukin J
Cancer; 2015 May; 121(9):1499-507. PubMed ID: 25586788
[TBL] [Abstract][Full Text] [Related]
30. Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas.
Bayliss J; Mukherjee P; Lu C; Jain SU; Chung C; Martinez D; Sabari B; Margol AS; Panwalkar P; Parolia A; Pekmezci M; McEachin RC; Cieslik M; Tamrazi B; Garcia BA; La Rocca G; Santi M; Lewis PW; Hawkins C; Melnick A; David Allis C; Thompson CB; Chinnaiyan AM; Judkins AR; Venneti S
Sci Transl Med; 2016 Nov; 8(366):366ra161. PubMed ID: 27881822
[TBL] [Abstract][Full Text] [Related]
31. Pediatric Ependymoma.
Vitanza NA; Partap S
J Child Neurol; 2016 Oct; 31(12):1354-66. PubMed ID: 26503805
[TBL] [Abstract][Full Text] [Related]
32. Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival.
Lukashova-v Zangen I; Kneitz S; Monoranu CM; Rutkowski S; Hinkes B; Vince GH; Huang B; Roggendorf W
Acta Neuropathol; 2007 Mar; 113(3):325-37. PubMed ID: 17265049
[TBL] [Abstract][Full Text] [Related]
33. Expression and Clinical Significance of Translation Regulatory Long Non-Coding RNA 1 (TRERNA1) in Ependymomas.
Malgulwar PB; Nambirajan A; Singh M; Suri V; Sarkar C; Sharma MC
Pathol Oncol Res; 2020 Jul; 26(3):1975-1981. PubMed ID: 31489574
[TBL] [Abstract][Full Text] [Related]
34. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
Pajtler KW; Wen J; Sill M; Lin T; Orisme W; Tang B; Hübner JM; Ramaswamy V; Jia S; Dalton JD; Haupfear K; Rogers HA; Punchihewa C; Lee R; Easton J; Wu G; Ritzmann TA; Chapman R; Chavez L; Boop FA; Klimo P; Sabin ND; Ogg R; Mack SC; Freibaum BD; Kim HJ; Witt H; Jones DTW; Vo B; Gajjar A; Pounds S; Onar-Thomas A; Roussel MF; Zhang J; Taylor JP; Merchant TE; Grundy R; Tatevossian RG; Taylor MD; Pfister SM; Korshunov A; Kool M; Ellison DW
Acta Neuropathol; 2018 Aug; 136(2):211-226. PubMed ID: 29909548
[TBL] [Abstract][Full Text] [Related]
35. Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features - a retrospective analysis of the HIT ependymoma trial cohort.
Jünger ST; Mynarek M; Wohlers I; Dörner E; Mühlen AZ; Velez-Char N; von Hoff K; Rutkowski S; Warmuth-Metz M; Kortmann RD; Timmermann B; Rahmann S; Klein-Hitpass L; von Bueren AO; Pietsch T
Acta Neuropathol Commun; 2019 Nov; 7(1):181. PubMed ID: 31727173
[TBL] [Abstract][Full Text] [Related]
36. Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas.
Pohl LC; Leitheiser M; Obrecht D; Schweizer L; Wefers AK; Eckhardt A; Raffeld M; Sturm D; Pajtler KW; Rutkowski S; Fukuoka K; Ichimura K; Bockmayr M; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):24. PubMed ID: 38265522
[TBL] [Abstract][Full Text] [Related]
37. Molecular subgrouping of ependymoma across three anatomic sites and their prognostic implications.
Chinnam D; Gupta K; Kiran T; Saraswati A; Salunke P; Madan R; Kumar N; Radotra BD
Brain Tumor Pathol; 2022 Jul; 39(3):151-161. PubMed ID: 35348910
[TBL] [Abstract][Full Text] [Related]
38. Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: A multicenter study.
Donson AM; Bertrand KC; Riemondy KA; Gao D; Zhuang Y; Sanford B; Norris GA; Chapman RJ; Fu R; Willard N; Griesinger AM; Ribeiro de Sousa G; Amani V; Grimaldo E; Hankinson TC; Booker F; Sill M; Grundy RG; Pajtler KW; Ellison DW; Foreman NK; Ritzmann TA
Neuro Oncol; 2023 Oct; 25(10):1854-1867. PubMed ID: 37246777
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of E2F-1 is associated with increased disease-free survival in squamous cell carcinoma of the anterior tongue.
Kwong RA; Nguyen TV; Bova RJ; Kench JG; Cole IE; Musgrove EA; Henshall SM; Sutherland RL
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3705-11. PubMed ID: 14506162
[TBL] [Abstract][Full Text] [Related]
40. Altered MicroRNA Expression Is Associated with Tumor Grade, Molecular Background and Outcome in Childhood Infratentorial Ependymoma.
Zakrzewska M; Fendler W; Zakrzewski K; Sikorska B; Grajkowska W; Dembowska-Bagińska B; Filipek I; Stefańczyk Ł; Liberski PP
PLoS One; 2016; 11(7):e0158464. PubMed ID: 27390862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]